Hmn-372 Extra Quality 〈1080p 2024〉

The revelation sparked a eureka moment. Could HMN-372 be more than just a random genetic anomaly? Was it, in fact, a key to understanding a hidden aspect of human biology, perhaps even a gene that could unlock regenerative capabilities?

| Year | Milestone | Key Insight | |------|-----------|-------------| | | Discovery of the HMN scaffold (high‑throughput screen of 1.2 M compounds) | Hit identified with sub‑micromolar inhibition of NLRP3 ATPase activity | | 2018‑2019 | Medicinal chemistry optimisation (SAR, PK, BBB permeability) | HMN‑372 emerged with >30‑fold potency gain and >90 % brain/plasma ratio in rodents | | 2020 | IND‑enabling toxicology (2‑month repeat‑dose in rats & dogs) | No target‑organ toxicity; NOAEL ≥ 100 mg/kg | | 2021 | IND filing with FDA & EMA | Granted Fast Track designation for AD in Q4 2021 | | 2022 | Phase I (single‑ascending dose, healthy volunteers) | Linear PK, t½ ≈ 12 h, <10 % inter‑subject variability; no serious AEs | | 2023 | Phase Ib (Mild‑moderate AD, n=45) | Statistically significant ↓ CSF IL‑1β (‑38 % vs placebo, p=0.01) and modest cognitive benefit (ADAS‑Cog12 Δ +1.4) | | 2024 | Phase IIa (PD with REM sleep behavior disorder, n=78) | Primary endpoint (UPDRS‑III off‑med) met with Δ ‑3.2 points (p=0.04); biomarker panel showed ↓ neurofilament light chain | | 2025‑2026 | Ongoing Phase IIb/III platform trials (AD, PD, Major Depressive Disorder) | Enrolment >1,200 participants across 30 sites worldwide | HMN-372